Functional interplay between melatonin receptor-mediated antiproliferative signaling and androgen receptor signaling in human prostate epithelial cells: Potential implications for therapeutic strategies against prostate cancer

Journal of Pineal Research

Volumn 51, Issue 3, 2011, Pages 297-312

  Tam, Chun W ^a,b   Shiu, Stephen Y W ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b OPEN UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

androgen receptor; melatonin; MT 1 receptor; p27 Kip1; prostate

Indexed keywords

ANDROGEN RECEPTOR; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 1B; MELATONIN 1 RECEPTOR; PROTEIN KINASE C;

ARTICLE; CELL PROLIFERATION; HORMONE ACTION; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN CELL; PROSTATE CANCER; PROSTATE EPITHELIUM;

CELL LINE, TUMOR; CELL PROLIFERATION; EPITHELIAL CELLS; HUMANS; MALE; MELATONIN; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RECEPTORS, MELATONIN; SIGNAL TRANSDUCTION;

EID: 80053163223     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/j.1600-079X.2011.00890.x     Document Type: Article

References (64)

1. Jemal A, Siegel R, Ward E, et al., Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Sarkar F, Li Y, Wang Z, et al., Novel targets for prostate cancer chemoprevention. Endocr Relat Cancer 2010; 17: R195-R212.
3. Shiu SYW, Pang B, Tam CW, et al., Signal transduction of receptor-mediated antiproliferative action of melatonin on human prostate epithelial cells involves dual activation of Gαs and Gαq proteins. J Pineal Res 2010; 49: 301-311.
4. Straif K, Baan R, Grosse Y, et al., Carcinogenicity of shift-work, painting, and fire-fighting. Lancet Oncol 2007; 8: 1065-1066.
5. Stevens RG,. Light-at-night, circadian disruption and breast cancer: assessment of existing evidence. Int J Epidemiol 2009; 38: 963-970.
6. Kubo T, Ozasa K, Mikami K, et al., Prospective cohort study of the risk of prostate cancer among rotating-shift workers: findings from the Japan collaborative. Am J Epidemiol 2006; 164: 549-555. (Pubitemid 44412783)
7. Conlon M, Lightfoot N, Kreiger N,. Rotating shift work and risk of prostate cancer. Epidemiology 2007; 18: 182-183. (Pubitemid 46005923)
8. Blask DE,. Melatonin, sleep disturbance and cancer risk. Sleep Med Rev 2009; 13: 257-264.
9. Reiter RJ, Tan DX, Erren TC, et al., Light-mediated perturbations of circadian timing and cancer risk: a mechanistic analysis. Integr Cancer Ther 2009; 8: 354-360.
10. Wu J, Dauchy RT, Tirrell PC, et al., Light at night activates IGF-1R/PDK1 signaling and accelerates tumor growth in human breast cancer xenografts. Cancer Res 2011; 71: 2622-2631.
11. Blask DE, Brainard GC, Dauchy RT, et al., Melatonin-depleted blood from premenopausal women exposed to light at night stimulates growth of human breast cancer xenografts in nude rats. Cancer Res 2005; 65: 11174-11184. (Pubitemid 41713389)
12. Srinivasan V, Spence DW, Pandi-Perumal SR, et al., Therapeutic actions of melatonin in cancer: possible mechanisms. Integr Cancer Ther 2008; 7: 189-203.
13. Mediavilla MD, Sanchez-Barcelo EJ, Tan DX, et al., Basic mechanisms involved in the anti-cancer effects of melatonin. Curr Med Chem 2010; 17: 4462-4481.
14. Kloog I, Haim A, Stevens RG, et al., Global co-distribution of light at night (LAN) and cancers of prostate, colon, and lung in men. Chronobiol Int 2009; 26: 108-125.
15. Reiter RJ, Tan DX, Korkmaz A, et al., Light at night, chronodisruption, melatonin suppression, and cancer risk: a review. Crit Rev Oncog 2007; 13: 303-328. (Pubitemid 351655045)
16. Shiu SYW,. Towards rational and evidence-based use of melatonin in prostate cancer prevention and treatment. J Pineal Res 2007; 43: 1-9. (Pubitemid 47035226)
17. 1 receptor and attenuated sex-steroid-induced calcium influx in the direct anti-proliferative action of melatonin on androgen-responsive LNCaP human prostate cancer cells. J Pineal Res 2000; 29: 172-183.
18. 1 receptor protein expression. Prostate 2001; 46: 52-61. (Pubitemid 32157776)
19. Siu SWF, Lau KW, Tam PC, et al., Melatonin and prostate cancer cell proliferation: Interplay with castration, epidermal growth factor, and androgen sensitivity. Prostate 2002; 52: 106-122. [Erratum, Prostate 2002; 52:252.]. (Pubitemid 34663323)
20. Shiu SYW, Law IC, Lau KW, et al., Melatonin slowed the early biochemical progression of hormone-refractory prostate cancer in a patient whose prostate tumor tissue expressed MT1 receptor subtype. J Pineal Res 2003; 35: 177-182. (Pubitemid 37100395)
21. Tam CW, Mo CW, Yao KM, et al., Signaling mechanisms of melatonin in antiproliferation of hormone-refractory 22Rv1 human prostate cancer cells: implications for prostate cancer chemoprevention. J Pineal Res 2007; 42: 191-202. (Pubitemid 46233066)
22. Tam CW, Chan KW, Liu VW, et al., Melatonin as a negative mitogenic hormonal regulator of human prostate epithelial cell growth: potential mechanisms and clinical significance. J Pineal Res 2008; 45: 403-412.
23. Chen Y, Clegg NJ, Scher HI,. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol 2009; 10: 981-991.
24. Miyamoto H, Messing EM, Chang C,. Androgen deprivation therapy for prostate cancer: current status and future prospects. Prostate 2004; 61: 332-353. (Pubitemid 39571710)
25. Attard G, Cooper CS, De Bono JS,. Steroid hormone receptors in prostate cancer: a hard habit to break? Cancer Cell 2009; 16: 458-462.
26. Perez-Stable CM, Pozas A, Roos BA,. A role for GATA transcription factors in the androgen regulation of the prostate-specific antigen gene enhancer. Mol Cell Endocrinol 2000; 167: 43-53.
27. Bello D, Webber MM, Kleinman HK, et al., Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Carcinogenesis 1997; 18: 1215-1223. (Pubitemid 28132513)
28. Veldscholte J, Ris-Stalpers C, Kuiper GG, et al., A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 1990; 173: 534-540.
29. Tepper CG, Boucher DL, Ryan PE, et al., Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res 2002; 62: 6606-6614. (Pubitemid 35364127)
30. Van Bokhoven A, Varella-Garcia M, Korch C, et al., Molecular characterization of human prostate carcinoma cell lines. Prostate 2003; 57: 205-225. (Pubitemid 37267805)
31. Liu W, Xie CC, Zhu Y, et al., Homozygous deletions and recurrent amplifications implicate new genes involved in prostate cancer. Neoplasia 2008; 10: 897-907.
32. Nelson WG, De Marzo AM, Isaacs WB,. Prostate cancer. N Engl J Med 2003; 349: 366-381. (Pubitemid 36886244)
33. Horoszewicz JS, Leong SS, Chu TM, et al., The LNCaP cell line-a new model for studies on human prostatic carcinoma. Prog Clin Biol Res 1980; 37: 115-132.
34. Chlenski A, Nakashiro K, Ketels KV, et al., Androgen receptor expression in androgen-independent prostate cancer cell lines. Prostate 2001; 47: 66-75. (Pubitemid 32246754)
35. Dehm SM, Schmidt LJ, Heemers HV, et al., Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 2008; 68: 5469-5477.
36. Marcias G, Erdmann E, Lapouge G, et al., Identification of novel truncated androgen receptor (AR) mutants including unreported pre-mRNA splicing variants in the 22Rv1 hormone-refractory prostate cancer (PCa) cell line. Hum Mutat 2010; 31: 74-80.
37. Hu R, Dunn TA, Wei S, et al., Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 2009; 69: 16-22.
38. Gilad E, Laufer M, Matzkin H, et al., Melatonin receptors in PC3 human prostate tumor cells. J Pineal Res 1999; 26: 211-220. (Pubitemid 29217237)
39. Marelli MM, Limonta P, Maggi R, et al., Growth-inhibitory activity of melatonin on human androgen-independent DU 145 prostate cancer cells. Prostate 2000; 45: 238-244.
40. Sainz RM, Mayo JC, Tan DX, et al., Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism. Prostate 2005; 63: 29-43. (Pubitemid 40365388)
41. Jung-Hynes B, Schmit TL, Reagan-Shaw SR, et al., Melatonin, a novel Sirt1 inhibitor, imparts antiproliferative effects against prostate cancer in vitro in culture and in vivo in TRAMP model. J Pineal Res 2011; 50: 140-149.
42. Kehrl JH, Sinnarajah S,. RGS2: a multifunctional regulator of G-protein signaling. Int J Biochem Cell Biol 2002; 34: 432-438. (Pubitemid 34242757)
43. Andrews PE, Young CY, Montgomery BT, et al., Tumor-promoting phorbol ester down-regulates the androgen induction of prostate-specific antigen in a human prostatic adenocarcinoma cell line. Cancer Res 1992; 52: 1525-1529.
44. Rimler A, Culig Z, Levy-Rimler G, et al., Melatonin elicits nuclear exclusion of the human androgen receptor and attenuates its activity. Prostate 2001; 49: 145-154. (Pubitemid 32937811)
45. Salama G, Noirot O, Bataille V, et al., French arm of the ERSPC study. Seasonality of serum prostate-specific antigen levels: a population-based study. Eur Urol 2007; 52: 708-714. (Pubitemid 47126126)
46. Tomlins SA, Rhodes DR, Perner S, et al., Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644-648. (Pubitemid 41528150)
47. Cerveira N, Ribeiro FR, Peixoto A, et al., TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia 2006; 8: 826-832. (Pubitemid 44564838)
48. Attard G, Reid AH, Olmos D, et al., Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res 2009; 69: 4937-4940.
49. Joo SS, Yoo YM,. Melatonin induces apoptotic death in LNCaP cells via p38 and JNK pathways: therapeutic implications for prostate cancer. J Pineal Res 2009; 47: 8-14.
50. Park JW, Hwang MS, Suh SI, et al., Melatonin down-regulates HIF-1 alpha expression through inhibition of protein translation in prostate cancer cells. J Pineal Res 2009; 46: 415-421.
51. Jung-Hynes B, Reiter RJ, Ahmad N,. Sirtuins, melatonin and circadian rhythms: building a bridge between aging and cancer. J Pineal Res 2010; 48: 9-19.
52. Jung-Hynes B, Huang W, Reiter RJ, et al., Melatonin resynchronizes dysregulated circadian rhythm circuitry in human prostate cancer cells. J Pineal Res 2010; 49: 60-68.
53. Cho SY, Lee HJ, Jeong SJ, et al., Sphingosine kinase 1 pathway is involved in melatonin-induced HIF-1α inactivation in hypoxic PC-3 prostate cancer cells. J Pineal Res 2011; February 1: doi:.
54. Mistraletti G, Sabbatini G, Taverna M, et al., Pharmacokinetics of orally administered melatonin in critically ill patients. J Pineal Res 2010; 48: 142-147.
55. Mohler JL, Gregory CW, Ford OH III, et al., The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004; 10: 440-448. (Pubitemid 38173980)
56. Stanbrough M, Bubley GJ, Ross K, et al., Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006; 66: 2815-2825.
57. Attard G, Reid AH, A'Hern R, et al., Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009; 27: 3742-3748.
58. Tran C, Ouk S, Clegg NJ, et al., Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324: 787-790.
59. Scher HI, Beer TM, Higano CS, et al., Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010; 375: 1437-1446.
60. Thompson IM, Goodman PJ, Tangen CM, et al., The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215-224. (Pubitemid 36859473)
61. Andriole GL, Bostwick DG, Brawley OW, et al., Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010; 362: 1192-1202.
62. Walsh PC,. Chemoprevention of prostate cancer. N Engl J Med 2010; 362: 1237-1238.
63. Majumder PK, Grisanzio C, O'Connell F, et al., A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell 2008; 14: 146-155.
64. Fernández PL, Arce Y, Farré X, et al., Expression of p27/Kip1 is down-regulated in human prostate carcinoma progression. J Pathol 1999; 187: 563-566. (Pubitemid 29151998)